{
  "id": "cluster_0_docid3",
  "content": "New Italian health policy directive (EU-IT/THERA/2023/88734) requires real-time biomarker monitoring for all cellular therapies starting November 1st. The regulation specifically impacts patients receiving treatment at facilities with BSL-3 certification like Genovel Biocare. Enforcement will be handled through mandatory provider uploads to the national treatment registry.",
  "metadata": {
    "format": "policy_document"
  }
}